Prospective Application of AOC 1044 in the Management of Duchenne Muscular Dystrophy Suitable for Exon 44 Omission.

Published Date: 28 Dec 2023

Chief medical officer of Avidity Biosciences, Steve Hughes, MD, offered insight on newly disclosed positive topline data for AOC 1044, an experimental treatment for Duchenne muscular dystrophy.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New surgical method shows promising results for cervical cancer treatment

2.

Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth

3.

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

4.

Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer

5.

Can Prior Authorization Be Better With Artificial Intelligence?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot